CareDx (CDNA) announced that it has filed a patent infringement suit against Natera (NTRA) in the United States District Court for Delaware. CareDx is asserting U.S. Patent Numbers 9,845,497 and 8,703,652, that are exclusively licensed to CareDx from Stanford University. Stanford is joined in the suit as a necessary party because it is the registered owner of these patents. These patents cover non-invasive monitoring of organ transplant rejection through cell-free DNA analysis. CareDx is seeking all available remedies, including damages and injunctive relief. The suit asserts that Natera infringes through its marketing and performance of a test to analyze cell-free DNA from a transplant patient to inform rejection. CareDx secured an exclusive license to the technology when it acquired ImmunMetrix in 2014.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.